These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21935751)

  • 1. Comorbidities, treatment and ensuing survival in men with prostate cancer.
    Chamie K; Daskivich TJ; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
    J Gen Intern Med; 2012 May; 27(5):492-9. PubMed ID: 21935751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved prediction of long-term, other cause mortality in men with prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
    J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
    Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
    Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive treatment and risk of death among men diagnosed with metastatic prostate cancer at the Veterans Health Administration.
    Drake BF; Khan S; Wang M; Hicks V; Nichols K; Taylor M; Kim EH; Chang SH
    Ann Epidemiol; 2023 Mar; 79():24-31. PubMed ID: 36640917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
    Nanda A; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA; 2009 Aug; 302(8):866-73. PubMed ID: 19706860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
    Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
    Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
    Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
    J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer outcomes for men who present with symptoms at diagnosis.
    Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
    BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
    Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study.
    Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
    Urology; 2015 Jan; 85(1):92-100. PubMed ID: 25261048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of comorbidity on survival among men with localized prostate cancer.
    Albertsen PC; Moore DF; Shih W; Lin Y; Li H; Lu-Yao GL
    J Clin Oncol; 2011 Apr; 29(10):1335-41. PubMed ID: 21357791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.